The DOI matches its Crossref record; 198 of the 198 references it cites were found in a registry or an index.
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Open accessAbstract
The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic testing, risk stratification with nomograms and tumor multigene molecular testing, androgen deprivation therapy, secondary hormonal therapy, chemotherapy, and immunotherapy in patients with prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Self-citationIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Self-citationD'Amico, A. V. (1998) · JAMA · doi:10.1001/jama.280.11.969 · Cited by 4,523
Self-citationAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Petrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Self-citationIntegrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
Epstein, J. I., Egevad, L., Amin, M. B., Delahunt, B., Srigley, J. R., & Humphrey, P. A. (2016) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000530 · Cited by 3,236
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Self-citationChemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y.-H., Carducci, M., Liu, G., Jarrard, D. F., Eisenberger, M., Wong, Y.-N., Hahn, N., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,896
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Self-citationScreening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704174 · Cited by 2,308
The Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 among Ashkenazi Jews
Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L. C., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,281
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., Ritchie, A. W. S., Parker, C. C., Russell, J. M., Attard, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01037-5 · Cited by 1,978
Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Abiraterone for prostate cancer not previously treated with hormone therapy
James, N. D., de Bono, J. S., Spears, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Ritchie, A. W. S., Amos, C. L., Gilson, C., Jones, R. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702900 · Cited by 1,801
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603144 · Cited by 1,680
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,671
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Chen, B. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1458 · Cited by 1,656
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
Fizazi, K., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., Staffurth, J. N., North, S., Vogelzang, N. J., Saad, F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70379-0 · Cited by 1,384
A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score
Epstein, J. I., Zelefsky, M. J., Sjoberg, D. D., Nelson, J. B., Egevad, L., Magi-Galluzzi, C., Vickers, A. J., Parwani, A. V., Reuter, V. E., Fine, S. W., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.06.046 · Cited by 1,374
Self-citationRyan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369
Self-citationApalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Smith, M. R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J. N., Olmos, D., Mainwaring, P. N., Lee, J. Y., Uemura, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715546 · Cited by 1,344
Self-citationSaad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Zheng, M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh141 · Cited by 1,201
Berthold, D. R., Pond, G. R., Soban, F., de Wit, R., Eisenberger, M., & Tannock, I. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4008 · Cited by 1,145
Kyriakopoulos, C. E., Chen, Y.-H., Carducci, M. A., Liu, G., Jarrard, D. F., Hahn, N. M., Shevrin, D. H., Dreicer, R., Hussain, M., Eisenberger, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3657 · Cited by 1,104
Self-citationCancer Incidence in BRCA1 Mutation Carriers
Thompson, D. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1358 · Cited by 1,096
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Hussain, M., Fizazi, K., Saad, F., Rathenborg, P., Shore, N., Ferreira, U., Ivashchenko, P., Demirhan, E., Modelska, K., Phung, D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800536 · Cited by 1,035
Kohler, B. A., Sherman, R. L., Howlader, N., Jemal, A., Ryerson, A. B., Henry, K. A., Boscoe, F. P., Cronin, K. A., Lake, A., Noone, A.-M., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv048 · Cited by 915
Castro, E., Goh, C., Olmos, D., Saunders, E., Leongamornlert, D., Tymrakiewicz, M., Mahmud, N., Dadaev, T., Govindasami, K., Guy, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1882 · Cited by 850
Development and Validation of a Prognostic Index for 4-Year Mortality in Older Adults
Lee, S. J. (2006) · JAMA · doi:10.1001/jama.295.7.801 · Cited by 809
Cuzick, J., Swanson, G. P., Fisher, G., Brothman, A. R., Berney, D. M., Reid, J. E., Mesher, D., Speights, V., Stankiewicz, E., Foster, C. S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70295-3 · Cited by 792
Postoperative Nomogram for Disease Recurrence After Radical Prostatectomy for Prostate Cancer
Kattan, M. W., Wheeler, T. M., & Scardino, P. T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1499 · Cited by 741
Dearnaley, D. P., Khoo, V. S., Norman, A. R., Meyer, L., Nahum, A., Tait, D., Yarnold, J., & Horwich, A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05180-0 · Cited by 739
The Androgen Axis in Recurrent Prostate Cancer
Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1146-03 · Cited by 675
Self-citationGermline Mutations in HOXB13 and Prostate-Cancer Risk
Ewing, C. M., Ray, A. M., Lange, E. M., Zuhlke, K. A., Robbins, C. M., Tembe, W. D., Wiley, K. E., Isaacs, S. D., Johng, D., Wang, Y., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110000 · Cited by 658
Erho, N., Crisan, A., Vergara, I. A., Mitra, A. P., Ghadessi, M., Buerki, C., Bergstralh, E. J., Kollmeyer, T., Fink, S., Haddad, Z., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066855 · Cited by 644
Stephenson, A. J., Scardino, P. T., Eastham, J. A., Bianco, F. J., Dotan, Z. A., Fearn, P. A., & Kattan, M. W. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj190 · Cited by 623
Self-citationMicrosatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer
Latham, A., Srinivasan, P., Kemel, Y., Shia, J., Bandlamudi, C., Mandelker, D., Middha, S., Hechtman, J., Zehir, A., Dubard-Gault, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00283 · Cited by 616
Attard, G., Reid, A. H. M., A'Hern, R., Parker, C., Oommen, N. B., Folkerd, E., Messiou, C., Molife, L. R., Maier, G., Thompson, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0642 · Cited by 605
Holzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L., Ryan, C., Smith, S., Scher, H., Scardino, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63112-4 · Cited by 577
Loblaw, D. A., Virgo, K. S., Nam, R., Somerfield, M. R., Ben-Josef, E., Mendelson, D. S., Middleton, R., Sharp, S. A., Smith, T. J., Talcott, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1949 · Cited by 555
Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian
Mersch, J., Jackson, M. A., Park, M., Nebgen, D., Peterson, S. K., Singletary, C., Arun, B. K., & Litton, J. K. (2015) · Cancer · doi:10.1002/cncr.29041 · Cited by 511
Hussain, M., Tangen, C. M., Higano, C., Schelhammer, P. F., Faulkner, J., Crawford, E. D., Wilding, G., Akdas, A., Small, E. J., Donnelly, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4246 · Cited by 505
Self-citationSmall, E. J., Halabi, S., Dawson, N. A., Stadler, W. M., Rini, B. I., Picus, J., Gable, P., Torti, F. M., Kaplan, E., & Vogelzang, N. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.037 · Cited by 504
Self-citationMakarov, D. V., Trock, B. J., Humphreys, E. B., Mangold, L. A., Walsh, P. C., Epstein, J. I., & Partin, A. W. (2007) · Urology · doi:10.1016/j.urology.2007.03.042 · Cited by 483
Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations
Jemal, A., Fedewa, S. A., Ma, J., Siegel, R., Lin, C. C., Brawley, O., & Ward, E. M. (2015) · JAMA · doi:10.1001/jama.2015.14905 · Cited by 469
A recurrent mutation in PALB2 in Finnish cancer families
Erkko, H., Xia, B., Nikkilä, J., Schleutker, J., Syrjäkoski, K., Mannermaa, A., Kallioniemi, A., Pylkäs, K., Karppinen, S.-M., Rapakko, K., et al. (2007) · Nature · doi:10.1038/nature05609 · Cited by 466
Beer, T. M., Armstrong, A. J., Rathkopf, D., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Evans, C. P., Kim, C.-S., Kimura, G., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.07.032 · Cited by 424
Self-citationCancer risks in BRCA2 families: estimates for sites other than breast and ovary
van Asperen, C. J., Brohet, R. M., Meijers-Heijboer, E. J., Hoogerbrugge, N., Verhoef, S., Vasen, H. F. A., Ausems, M. G. E. M., Menko, F. H., Gomez Garcia, E. B., Klijn, J. G. M., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.028829 · Cited by 420
Stephenson, A. J., Kattan, M. W., Eastham, J. A., Bianco, F. J., Yossepowitch, O., Vickers, A. J., Klein, E. A., Wood, D. P., & Scardino, P. T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.2501 · Cited by 419
Self-citationCancer Risks for Male Carriers of Germline Mutations in BRCA1 or BRCA2: A Review of the Literature
Liede, A., Karlan, B. Y., & Narod, S. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.055 · Cited by 407
CAGIANNOS, I., KARAKIEWICZ, P., EASTHAM, J. A., OHORI, M., RABBANI, F., GERIGK, C., REUTER, V., GRAEFEN, M., HAMMERER, P. G., ERBERSDOBLER, A., et al. (2003) · Journal of Urology · doi:10.1097/01.ju.0000091805.98960.13 · Cited by 402
Self-citationZumsteg, Z. S., Spratt, D. E., Pei, I., Zhang, Z., Yamada, Y., Kollmeier, M., & Zelefsky, M. J. (2013) · European Urology · doi:10.1016/j.eururo.2013.03.033 · Cited by 397
Self-citationClarke, N., Wiechno, P., Alekseev, B., Sala, N., Jones, R., Kocak, I., Chiuri, V. E., Jassem, J., Fléchon, A., Redfern, C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30365-6 · Cited by 396
Reid, A. H. M., Attard, G., Danila, D. C., Oommen, N. B., Olmos, D., Fong, P. C., Molife, L. R., Hunt, J., Messiou, C., Parker, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6819 · Cited by 394
Self-citationD'Amico, A. V., Whittington, R., Malkowicz, S. B., Fondurulia, J., Chen, M.-H., Kaplan, I., Beard, C. J., Tomaszewski, J. E., Renshaw, A. A., Wein, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.168 · Cited by 389
Self-citationTendulkar, R. D., Agrawal, S., Gao, T., Efstathiou, J. A., Pisansky, T. M., Michalski, J. M., Koontz, B. F., Hamstra, D. A., Feng, F. Y., Liauw, S. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.9647 · Cited by 380
Castro, E., Romero-Laorden, N., del Pozo, A., Lozano, R., Medina, A., Puente, J., Piulats, J. M., Lorente, D., Saez, M. I., Morales-Barrera, R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00358 · Cited by 377
Castro, E., Goh, C., Leongamornlert, D., Saunders, E., Tymrakiewicz, M., Dadaev, T., Govindasami, K., Guy, M., Ellis, S., Frost, D., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.10.022 · Cited by 368
Nicolosi, P., Ledet, E., Yang, S., Michalski, S., Freschi, B., O’Leary, E., Esplin, E. D., Nussbaum, R. L., & Sartor, O. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.6760 · Cited by 365
on behalf of the Transatlantic Prostate Group, Cuzick, J., Berney, D. M., Fisher, G., Mesher, D., Møller, H., Reid, J. E., Perry, M., Park, J., Younus, A., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.39 · Cited by 364
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
Hansen, A. R., Massard, C., Ott, P. A., Haas, N. B., Lopez, J. S., Ejadi, S., Wallmark, J. M., Keam, B., Delord, J.-P., Aggarwal, R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy232 · Cited by 363
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
Graff, J. N., Alumkal, J. J., Drake, C. G., Thomas, G. V., Redmond, W. L., Farhad, M., Cetnar, J. P., Ey, F. S., Bergan, R. C., Slottke, R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10547 · Cited by 359
Oudard, S., Fizazi, K., Sengeløv, L., Daugaard, G., Saad, F., Hansen, S., Hjälm-Eriksson, M., Jassem, J., Thiery-Vuillemin, A., Caffo, O., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1068 · Cited by 357
D'Amico, A. V., Whittington, R., Malkowicz, S. B., Cote, K., Loffredo, M., Schultz, D., Chen, M., Tomaszewski, J. E., Renshaw, A. A., Wein, A., et al. (2002) · Cancer · doi:10.1002/cncr.10657 · Cited by 356
Self-citationCooperberg, M. R., Simko, J. P., Cowan, J. E., Reid, J. E., Djalilvand, A., Bhatnagar, S., Gutin, A., Lanchbury, J. S., Swanson, G. P., Stone, S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.4396 · Cited by 351
KATTAN, M. W., EASTHAM, J. A., WHEELER, T. M., MARU, N., SCARDINO, P. T., ERBERSDOBLER, A., GRAEFEN, M., HULAND, H., KOH, H., SHARIAT, S. F., et al. (2003) · Journal of Urology · doi:10.1097/01.ju.0000091806.70171.41 · Cited by 350
Self-citationLotan, T. L., Gurel, B., Sutcliffe, S., Esopi, D., Liu, W., Xu, J., Hicks, J. L., Park, B. H., Humphreys, E., Partin, A. W., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1244 · Cited by 348
Self-citationNa, R., Zheng, S. L., Han, M., Yu, H., Jiang, D., Shah, S., Ewing, C. M., Zhang, L., Novakovic, K., Petkewicz, J., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.11.033 · Cited by 343
Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist
Albertsen, P. C., Klotz, L., Tombal, B., Grady, J., Olesen, T. K., & Nilsson, J. (2014) · European Urology · doi:10.1016/j.eururo.2013.10.032 · Cited by 341
Karnes, R. J., Bergstralh, E. J., Davicioni, E., Ghadessi, M., Buerki, C., Mitra, A. P., Crisan, A., Erho, N., Vergara, I. A., Lam, L. L., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.06.017 · Cited by 325
Gandaglia, G., Ploussard, G., Valerio, M., Mattei, A., Fiori, C., Fossati, N., Stabile, A., Beauval, J.-B., Malavaud, B., Roumiguié, M., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.10.012 · Cited by 322
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
Penson, D. F., Armstrong, A. J., Concepcion, R., Agarwal, N., Olsson, C., Karsh, L., Dunshee, C., Wang, F., Wu, K., Krivoshik, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.9285 · Cited by 319
Self-citationCullen, J., Rosner, I. L., Brand, T. C., Zhang, N., Tsiatis, A. C., Moncur, J., Ali, A., Chen, Y., Knezevic, D., Maddala, T., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.11.030 · Cited by 310
Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations
Moran, A., O’Hara, C., Khan, S., Shack, L., Woodward, E., Maher, E. R., Lalloo, F., & Evans, D. G. R. (2012) · Familial Cancer · doi:10.1007/s10689-011-9506-2 · Cited by 307
Germline BRCA1 mutations increase prostate cancer risk
Collaborators, T. U., Leongamornlert, D., Mahmud, N., Tymrakiewicz, M., Saunders, E., Dadaev, T., Castro, E., Goh, C., Govindasami, K., Guy, M., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.146 · Cited by 302
Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer
Gallagher, D. J., Gaudet, M. M., Pal, P., Kirchhoff, T., Balistreri, L., Vora, K., Bhatia, J., Stadler, Z., Fine, S. W., Reuter, V., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2871 · Cited by 301
Self-citationPredicting the Presence and Side of Extracapsular Extension: A Nomogram for Staging Prostate Cancer
OHORI, M., KATTAN, M. W., KOH, H., MARU, N., SLAWIN, K. M., SHARIAT, S., MURAMOTO, M., REUTER, V. E., WHEELER, T. M., & SCARDINO, P. T. (2004) · Journal of Urology · doi:10.1097/01.ju.0000121693.05077.3d · Cited by 297
Eisenberger, M., Hardy-Bessard, A.-C., Kim, C. S., Géczi, L., Ford, D., Mourey, L., Carles, J., Parente, P., Font, A., Kacso, G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1076 · Cited by 292
Logothetis, C. J., Basch, E., Molina, A., Fizazi, K., North, S. A., Chi, K. N., Jones, R. J., Goodman, O. B., Mainwaring, P. N., Sternberg, C. N., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70473-4 · Cited by 280
Shore, N. D., Chowdhury, S., Villers, A., Klotz, L., Siemens, D. R., Phung, D., van Os, S., Hasabou, N., Wang, F., Bhattacharya, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00518-5 · Cited by 278
Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer
MCLEOD, D. G., IVERSEN, P., SEE, W. A., MORRIS, T., ARMSTRONG, J., WIRTH, M. P., & the Casodex Early Prostate Cancer Trialists’ Group (2006) · BJU International · doi:10.1111/j.1464-410x.2005.06051.x · Cited by 277
Prensner, J. R., Zhao, S., Erho, N., Schipper, M., Iyer, M. K., Dhanasekaran, S. M., Magi-Galluzzi, C., Mehra, R., Sahu, A., Siddiqui, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71113-1 · Cited by 264
Cheng, H. H., Pritchard, C. C., Boyd, T., Nelson, P. S., & Montgomery, B. (2016) · European Urology · doi:10.1016/j.eururo.2015.11.022 · Cited by 261
Samson, D. J., Seidenfeld, J., Schmitt, B., Hasselblad, V., Albertsen, P. C., Bennett, C. L., Wilt, T. J., & Aronson, N. (2002) · Cancer · doi:10.1002/cncr.10647 · Cited by 259
Pomerantz, M. M., Spisák, S., Jia, L., Cronin, A. M., Csabai, I., Ledet, E., Sartor, A. O., Rainville, I., O'Connor, E. P., Herbert, Z. T., et al. (2017) · Cancer · doi:10.1002/cncr.30808 · Cited by 257
Smith, M. R., Halabi, S., Ryan, C. J., Hussain, A., Vogelzang, N., Stadler, W., Hauke, R. J., Monk, J. P., Saylor, P., Bhoopalam, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.6500 · Cited by 251
Self-citationSpratt, D. E., Yousefi, K., Deheshi, S., Ross, A. E., Den, R. B., Schaeffer, E. M., Trock, B. J., Zhang, J., Glass, A. G., Dicker, A. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.2811 · Cited by 247
Self-citationRoss, A. E., Johnson, M. H., Yousefi, K., Davicioni, E., Netto, G. J., Marchionni, L., Fedor, H. L., Glavaris, S., Choeurng, V., Buerki, C., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.05.042 · Cited by 243
Self-citationFizazi, K., Faivre, L., Lesaunier, F., Delva, R., Gravis, G., Rolland, F., Priou, F., Ferrero, J.-M., Houede, N., Mourey, L., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00011-x · Cited by 239
Negoita, S., Feuer, E. J., Mariotto, A., Cronin, K. A., Petkov, V. I., Hussey, S. K., Benard, V., Henley, S. J., Anderson, R. N., Fedewa, S., et al. (2018) · Cancer · doi:10.1002/cncr.31549 · Cited by 239
Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories
Taylor, R. A., Fraser, M., Livingstone, J., Espiritu, S. M. G., Thorne, H., Huang, V., Lo, W., Shiah, Y.-J., Yamaguchi, T. N., Sliwinski, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms13671 · Cited by 234
Gandaglia, G., Fossati, N., Zaffuto, E., Bandini, M., Dell’Oglio, P., Bravi, C. A., Fallara, G., Pellegrino, F., Nocera, L., Karakiewicz, P. I., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.03.049 · Cited by 233
Prostate Cancer Progression and Survival in BRCA2 Mutation Carriers
Tryggvadottir, L., Vidarsdottir, L., Thorgeirsson, T., Jonasson, J. G., Olafsdottir, E. J., Olafsdottir, G. H., Rafnar, T., Thorlacius, S., Jonsson, E., Eyfjord, J. E., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm005 · Cited by 231
Taneja, S. S. (2015) · Journal of Urology · doi:10.1016/j.juro.2015.02.070 · Cited by 228
Duchesne, G. M., Woo, H. H., Bassett, J. K., Bowe, S. J., D'Este, C., Frydenberg, M., King, M., Ledwich, L., Loblaw, A., Malone, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00107-8 · Cited by 219
Zhao, S. G., Chang, S. L., Spratt, D. E., Erho, N., Yu, M., Ashab, H. A.-D., Alshalalfa, M., Speers, C., Tomlins, S. A., Davicioni, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30491-0 · Cited by 213
Self-citationKellokumpu-Lehtinen, P.-L., Harmenberg, U., Joensuu, T., McDermott, R., Hervonen, P., Ginman, C., Luukkaa, M., Nyandoto, P., Hemminki, A., Nilsson, S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70537-5 · Cited by 212
Den, R. B., Yousefi, K., Trabulsi, E. J., Abdollah, F., Choeurng, V., Feng, F. Y., Dicker, A. P., Lallas, C. D., Gomella, L. G., Davicioni, E., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0026 · Cited by 211
Spratt, D. E., Zhang, J., Santiago-Jiménez, M., Dess, R. T., Davis, J. W., Den, R. B., Dicker, A. P., Kane, C. J., Pollack, A., Stoyanova, R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.2940 · Cited by 211
Self-citationFizazi, K., Scher, H. I., Miller, K., Basch, E., Sternberg, C. N., Cella, D., Forer, D., Hirmand, M., & de Bono, J. S. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70303-1 · Cited by 208
Cooperberg, M. R., Davicioni, E., Crisan, A., Jenkins, R. B., Ghadessi, M., & Karnes, R. J. (2015) · European Urology · doi:10.1016/j.eururo.2014.05.039 · Cited by 194
Drazer, M. W., Huo, D., & Eggener, S. E. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.6532 · Cited by 194
Bishoff, J. T., Freedland, S. J., Gerber, L., Tennstedt, P., Reid, J., Welbourn, W., Graefen, M., Sangale, Z., Tikishvili, E., Park, J., et al. (2014) · Journal of Urology · doi:10.1016/j.juro.2014.02.003 · Cited by 191
Klein, E. A., Yousefi, K., Haddad, Z., Choeurng, V., Buerki, C., Stephenson, A. J., Li, J., Kattan, M. W., Magi-Galluzzi, C., & Davicioni, E. (2015) · European Urology · doi:10.1016/j.eururo.2014.10.036 · Cited by 186
Freedland, S. J., Gerber, L., Reid, J., Welbourn, W., Tikishvili, E., Park, J., Younus, A., Gutin, A., Sangale, Z., Lanchbury, J. S., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.04.043 · Cited by 184
Szmulewitz, R. Z., Peer, C. J., Ibraheem, A., Martinez, E., Kozloff, M. F., Carthon, B., Harvey, R. D., Fishkin, P., Yong, W. P., Chiong, E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.4381 · Cited by 182
Loss-of-function variants in ATM confer risk of gastric cancer
Helgason, H., Rafnar, T., Olafsdottir, H. S., Jonasson, J. G., Sigurdsson, A., Stacey, S. N., Jonasdottir, A., Tryggvadottir, L., Alexiusdottir, K., Haraldsson, A., et al. (2015) · Nature Genetics · doi:10.1038/ng.3342 · Cited by 180
Blume-Jensen, P., Berman, D. M., Rimm, D. L., Shipitsin, M., Putzi, M., Nifong, T. P., Small, C., Choudhury, S., Capela, T., Coupal, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2603 · Cited by 179
Antonarakis, E. S., Lu, C., Luber, B., Liang, C., Wang, H., Chen, Y., Silberstein, J. L., Piana, D., Lai, Z., Chen, Y., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.01.035 · Cited by 179
Self-citationLecarpentier, J., Silvestri, V., Kuchenbaecker, K. B., Barrowdale, D., Dennis, J., McGuffog, L., Soucy, P., Leslie, G., Rizzolo, P., Navazio, A. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.4935 · Cited by 178
Chua, M. L. K., Lo, W., Pintilie, M., Murgic, J., Lalonde, E., Bhandari, V., Mahamud, O., Gopalan, A., Kweldam, C. F., van Leenders, G. J. L. H., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.04.034 · Cited by 177
Antonarakis, E. S., Shaukat, F., Isaacsson Velho, P., Kaur, H., Shenderov, E., Pardoll, D. M., & Lotan, T. L. (2019) · European Urology · doi:10.1016/j.eururo.2018.10.009 · Cited by 177
Self-citationAvascular necrosis of the jaws: risk factors in metastatic cancer patients
Tarassoff, P., & Csermak, K. (2003) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2003.09.001 · Cited by 175
Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype
Collaborators, T. I. A. E., Mitra, A., Fisher, C., Foster, C. S., Jameson, C., Barbachanno, Y., Bartlett, J., Bancroft, E., Doherty, R., Kote-Jarai, Z., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604132 · Cited by 173
Chi, K. N., Protheroe, A., Rodríguez-Antolín, A., Facchini, G., Suttman, H., Matsubara, N., Ye, Z., Keam, B., Damião, R., Li, T., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30911-7 · Cited by 172
Klotz, L., O'Callaghan, C., Ding, K., Toren, P., Dearnaley, D., Higano, C. S., Horwitz, E., Malone, S., Goldenberg, L., Gospodarowicz, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.2973 · Cited by 168
Self-citationMSH2 Loss in Primary Prostate Cancer
Guedes, L. B., Antonarakis, E. S., Schweizer, M. T., Mirkheshti, N., Almutairi, F., Park, J. C., Glavaris, S. A., Hicks, J. L., Eisenberger, M. A., Marzo, A. M. D., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0955 · Cited by 167
Self-citationBRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews
Kirchhoff, T., Kauff, N. D., Mitra, N., Nafa, K., Huang, H., Palmer, C., Gulati, T., Wadsworth, E., Donat, S., Robson, M. E., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0604 · Cited by 165
Bahl, A., Oudard, S., Tombal, B., Özgüroĝlu, M., Hansen, S., Kocak, I., Gravis, G., Devin, J., Shen, L., de Bono, J. S., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt194 · Cited by 163
Rapid progression of prostate cancer in men with a BRCA2 mutation
the Hereditary Breast Cancer Study Group, Narod, S. A., Neuhausen, S., Vichodez, G., Armel, S., Lynch, H. T., Ghadirian, P., Cummings, S., Olopade, O., Stoppa-Lyonnet, D., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604453 · Cited by 162
on behalf of the Transatlantic Prostate Group, Cuzick, J., Stone, S., Fisher, G., Yang, Z. H., North, B. V., Berney, D. M., Beltran, L., Greenberg, D., Møller, H., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.223 · Cited by 155
PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy
Lotan, T. L., Carvalho, F. L. F., Peskoe, S. B., Hicks, J. L., Good, J. L., Fedor, H. L., Humphreys, E. B., Han, M., Platz, E. A., Squire, J. A., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.85 · Cited by 152
Graefen, M., Haese, A., Pichlmeier, U., Hammerer, P. G., Noldus, J., Butz, K., Erbersdobler, A., Henke, R., Michl, U. H. G., Fernandez, S., et al. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)66544-5 · Cited by 152
Yamoah, K., Johnson, M. H., Choeurng, V., Faisal, F. A., Yousefi, K., Haddad, Z., Ross, A. E., Alshalafa, M., Den, R. B., Lal, P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.8912 · Cited by 152
Self-citationRosenthal, S. A., Hu, C., Sartor, O. A., Gomella, L. G., Amin, M. B., Purdy, J. A., Michalski, J. M., Garzotto, M. G., Pervez, N., Balogh, A. G., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02158 · Cited by 150
Self-citationDen, R. B., Feng, F. Y.-C., Showalter, T. N., Mishra, M. V., Trabulsi, E. J., Lallas, C. D., Gomella, L. G., Kelly, W. K., Birbe, R., McCue, P. A., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.04.052 · Cited by 149
Risbridger, G. P., Taylor, R. A., Clouston, D. R., Sliwinski, A., Thorne, H., Hunter, S. M., Li, J., Mitchell, G., Murphy, D. G., Frydenberg, M., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.08.007 · Cited by 149
Associations of High-Grade Prostate Cancer withBRCA1andBRCA2Founder Mutations
Agalliu, I., Gern, R. W., Leanza, S. M., & Burk, R. D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1822 · Cited by 147
Näslund‐Koch, C., Nordestgaard, B. G., & Bojesen, S. E. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.3594 · Cited by 141
Velho, P. I., Silberstein, J. L., Markowski, M. C., Luo, J., Lotan, T. L., Isaacs, W. B., & Antonarakis, E. S. (2018) · The Prostate · doi:10.1002/pros.23484 · Cited by 141
Self-citationRisk of Prostate Cancer in Lynch Syndrome: A Systematic Review and Meta-analysis
Ryan, S., Jenkins, M. A., & Win, A. K. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-1165 · Cited by 140
Tomlins, S. A., Alshalalfa, M., Davicioni, E., Erho, N., Yousefi, K., Zhao, S. G., Haddad, Z., Den, R. B., Dicker, A. P., Trock, B. J., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.04.033 · Cited by 136
Self-citationFred Saad, C., Cella, D. F., Basch, E., Hadaschik, B. A., Mainwaring, P. N., Oudard, S. M., Graff, J. N., McQuarrie, K., Li, S., Hudgens, S. A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30456-x · Cited by 133
Self-citationEeden, S. K. V. D., Lu, R., Zhang, N., Quesenberry, C. P., Shan, J., Han, J. S., Tsiatis, A. C., Leimpeter, A. D., Lawrence, H. J., Febbo, P. G., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.09.013 · Cited by 132
Böttcher, R., Kweldam, C. F., Livingstone, J. M., Lalonde, E., Yamaguchi, T. N., Huang, V., Yousif, F., Fraser, M. E., Bristow, R. G., van der Kwast, T., et al. (2018) · BMC Cancer · doi:10.1186/s12885-017-3976-z · Cited by 132
Punnen, S., Freedland, S. J., Presti, J. C., Aronson, W. J., Terris, M. K., Kane, C. J., Amling, C. L., Carroll, P. R., & Cooperberg, M. R. (2013) · European Urology · doi:10.1016/j.eururo.2013.03.058 · Cited by 129
Self-citationRoss, A. E., Feng, F. Y.-C., Ghadessi, M., Erho, N., Crisan, A., Buerki, C., Sundi, D., Mitra, A. P., Vergara, I. A., Thompson, D. J. S., et al. (2013) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2013.49 · Cited by 128
Self-citationProstate cancer risk prediction based on complete prostate cancer family history
Albright, F. S., Stephenson, R. A., Agarwal, N., Teerlink, C. C., Lowrance, W. T., Farnham, J. M., & Cannon‐Albright, L. (2014) · The Prostate · doi:10.1002/pros.22925 · Cited by 127
Mateo, J., Cheng, H. H., Beltran, H., Dolling, D. I., Xu, W., Pritchard, C. C., Mossop, H., Rescigno, P., Pérez-López, R., Sailer, V., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.01.010 · Cited by 127
Barocas, D. A., Mallin, K., Graves, A. J., Penson, D. F., Palis, B. E., Winchester, D. P., & Chang, S. S. (2015) · The Journal of Urology · doi:10.1016/j.juro.2015.06.075 · Cited by 126
Self-citationDinh, K. T., Mahal, B. A. V., Ziehr, D. R., Muralidhar, V., Chen, Y., Viswanathan, V. B., Nezolosky, M. D., Beard, C. J., Choueiri, T. K., Martin, N. E., et al. (2015) · The Journal of Urology · doi:10.1016/j.juro.2015.02.015 · Cited by 126
Oh, W. K., Kantoff, P. W., Weinberg, V., Jones, G., Rini, B. I., Derynck, M. K., Bok, R., Smith, M. R., Bubley, G. J., Rosen, R. T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.195 · Cited by 124
Self-citationSun, M., Choueiri, T. K., Hamnvik, O. R., Preston, M. A., de Velasco, G., Jiang, W., Loeb, S., Nguyen, P. L., & Trinh, Q. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4917 · Cited by 124
Labrie, F., Dupont, A., Bélanger, A., & Lachance, R. (1987) · The Journal of Urology · doi:10.1016/s0022-5347(17)43380-5 · Cited by 122
Tosoian, J. J., Chappidi, M. R., Feng, Z., Humphreys, E. B., Han, M., Pavlovich, C. P., Epstein, J. I., Partin, A. W., & Trock, B. J. (2016) · British Journal of Urology · doi:10.1111/bju.13573 · Cited by 121
Microsatellite instability in prostate cancer by PCR or next-generation sequencing
Hempelmann, J. A., Lockwood, C. M., Konnick, E. Q., Schweizer, M. T., Antonarakis, E. S., Lotan, T. L., Montgomery, B., Nelson, P. S., Klemfuss, N. M., Salipante, S. J., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0341-y · Cited by 117
Self-citationCOMPLETE ANDROGEN BLOCKADE FOR PROSTATE CANCER: WHAT WENT WRONG?
Laufer, M., Denmeade, S. R., Sinibaldi, V. J., Carducci, M. A., & Eisenberger, M. A. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)67436-8 · Cited by 116
Thorne, H., Willems, A. J., Niedermayr, E., Hoh, I., Li, J., Clouston, D. R., Mitchell, G., Fox, S. B., Hopper, J. L., & Bolton, D. M. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0397 · Cited by 111
Prostate cancer incidence in males with Lynch syndrome
Haraldsdóttir, S., Hampel, H., Wei, L., Wu, C. S.-Y., Frankel, W. L., Bekaii‐Saab, T., de la Chapelle, A., & Goldberg, R. M. (2014) · Genetics in Medicine · doi:10.1038/gim.2013.193 · Cited by 110
Giri, V. N., Hegarty, S., Hyatt, C., O’Leary, E., Garcia, J., Knudsen, K. E., Kelly, W. K., & Gomella, L. G. (2018) · The Prostate · doi:10.1002/pros.23739 · Cited by 109
TOMBAL, B. F., Fred Saad, C., Penson, D. F., Hussain, M., Sternberg, C. N., Morlock, R., Ramaswamy, K., Ivanescu, C., & Attard, G. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30898-2 · Cited by 109
Self-citationTrends in the Incidence of Fatal Prostate Cancer in the United States by Race
Kelly, S. P., Rosenberg, P. S., Anderson, W. F., Andreotti, G., Younes, N., Cleary, S. D., & Cook, M. B. (2016) · European Urology · doi:10.1016/j.eururo.2016.05.011 · Cited by 106
Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer
on behalf of the Transatlantic Prostate Group, Cuzick, J. M., Yang, Z., Fisher, G., Tikishvili, E., Stone, S., Lanchbury, J. S. S., Camacho, N., Merson, S., Brewer, D. S., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.248 · Cited by 105
Hager, S., Ackermann, C. J., Joerger, M., Gillessen, S., & Omlin, A. G. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw156 · Cited by 104
Khor, L.-Y., Bae, K., Paulus, R., Al-Saleem, T., Hammond, M. E., Grignon, D. J., Che, M., Venkatesan, V., Byhardt, R. W., Rotman, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8267 · Cited by 102
Ola Bratt, A., Drevin, L., Akre, O., Garmo, H., & Stattin, P. E. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw110 · Cited by 100
Kote‐Jarai, Z., Mikropoulos, C., Leongamornlert, D. A., Dadaev, T., Tymrakiewicz, M., Saunders, E. J., Jones, M. E., Jugurnauth-Little, S., Govindasami, K., Guy, M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv004 · Cited by 98
Transdermal Estradiol Therapy for Advanced Prostate Cancer—Forward to the Past?
Ockrim, J., Lalani, E., Laniado, M., Carter, S. S. C., & Abel, P. D. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000061024.75334.40 · Cited by 97
Lotan, T. L., Wei, W., Ludkovski, O., Morais, C. L., Guedes, L. B., Jamaspishvili, T., Lopez, K., Hawley, S. T., Feng, Z., Fazli, L., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.88 · Cited by 97
Self-citationLu‐Yao, G. L., Albertsen, P. C., Moore, D. F., Shih, W. J., Lin, Y., DiPaola, R. S., & Yao, S. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.3028 · Cited by 95
Langley, R. E., Cafferty, F. H., Alhasso, A. A., Rosen, S. D., Sundaram, S. K., Freeman, S. C., Pollock, P., Jinks, R. C., Godsland, I. F., Kockelbergh, R. C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70025-1 · Cited by 95
The effect of a single BRCA2 mutation on cancer in Iceland
Tulinius, H., Ólafsdóttir, G. H., Sigvaldason, H., Arason, A., Barkardottir, R. B., Egilsson, V., Ogmundsdottir, H. M., Tryggvadóttír, L., Gudlaugsdottir, S., & Eyfjord, J. E. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.7.457 · Cited by 89
James, N. D., Pirrie, S. J., Pope, A., Barton, D., Andronis, L., Goranitis, I., Collins, S. I., Daunton, A., McLaren, D. B., O’Sullivan, J. M., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5570 · Cited by 88
Freedland, S. J., Choeurng, V., Howard, L. E., Hoedt, A. M. D., du Plessis, M., Yousefi, K., Lam, L. L. C., Buerki, C., Ra, S., Robbins, B. A., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.01.008 · Cited by 80
Meisel, A., von Felten, S., Vogt, D., Liewen, H., de Wit, R., Bono, J. S. D., Sartor, O. A., & Stenner, F. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.009 · Cited by 80
Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate
Schweizer, M. T., Cheng, H. H., Tretiakova, M., Vakar‐Lopez, F., Klemfuss, N. M., Konnick, E. Q., Mostaghel, E. A., Nelson, P. S., Yu, E. Y., Montgomery, B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12697 · Cited by 80
Effectiveness of Primary Androgen-Deprivation Therapy for Clinically Localized Prostate Cancer
Potosky, A. L., Haque, R., Cassidy-Bushrow, A. E., Ulcickas Yood, M., Jiang, M., Tsai, H.-T., Luta, G., Keating, N. L., Smith, M. R., & Van Den Eeden, S. K. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.5782 · Cited by 75
Kearns, J. T., Holt, S. K., Wright, J. L., et al. (2018) · Cancer · doi:10.1002/cncr.31337 · Cited by 74
Karnes, R. J., Choeurng, V., Ross, A. E., Schaeffer, E. M., Klein, E. A., Freedland, S. J., Erho, N., Yousefi, K., Takhar, M. M., Davicioni, E., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.03.036 · Cited by 73
Self-citationA comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer
Wu, Y., Yu, H., Zheng, S. L., Na, R., Mamawala, M. K., Landis, T., Wiley, K. E., Petkewicz, J., Shah, S., Shi, Z., et al. (2018) · The Prostate · doi:10.1002/pros.23505 · Cited by 73
Troyer, D. A., Jamaspishvili, T., Wei, W., Feng, Z., Good, J. L., Hawley, S., Fazli, L., McKenney, J. K., Simko, J. P., Hurtado‐Coll, A., et al. (2015) · The Prostate · doi:10.1002/pros.23003 · Cited by 69
Self-citationGermline genetic variants in men with prostate cancer and one or more additional cancers
Pilie, P. G., Johnson, A., Hanson, K., Dayno, M., Kapron, A. L., Stoffel, E. M., & Cooney, K. A. (2017) · Cancer · doi:10.1002/cncr.30817 · Cited by 59
Fedewa, S. A., Ward, E., Brawley, O. W., & Jemal, A. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.0340 · Cited by 55
Tosoian, J. J., Chappidi, M. R., Bishoff, J. T., Freedland, S. J., Reid, J., Brawer, M. K., Stone, S., Schlomm, T., & Ross, A. E. (2017) · British Journal of Urology · doi:10.1111/bju.13911 · Cited by 53
Eggener, S. E., Karsh, L. I., Richardson, T., Shindel, A. W., Lu, R., Rosenberg, S., Goldfischer, E. R., Korman, H., Bennett, J. P., Newmark, J., et al. (2019) · Urology · doi:10.1016/j.urology.2018.11.050 · Cited by 53
Duchesne, G. M., Woo, H. H., King, M. T., Bowe, S. J., Stockler, M. R., Ames, A., D’Este, C. A., Frydenberg, M., Loblaw, A., Malone, S. C., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30426-6 · Cited by 52
Brand, T. C., Zhang, N., Crager, M., Maddala, T., Dee, A., Sesterhenn, I. A., Simko, J., Cooperberg, M. R., Srivastava, S. K., Rosner, I. L., et al. (2015) · Urology · doi:10.1016/j.urology.2015.12.008 · Cited by 51
McLeod, D. G., See, W. A., Klimberg, I. W., Gleason, D. M., Chodak, G. W., Montie, J. E., Bernstein, G., Morris, C. D., Armstrong, J., & Casodex™ Early Prostate Cancer Trialists’ Group (2006) · The Journal of Urology · doi:10.1016/s0022-5347(06)00495-2 · Cited by 46
Drug therapy for hereditary cancers
Имянитов, Е. Н., & Moiseyenko, V. M. (2011) · Hereditary Cancer in Clinical Practice · doi:10.1186/1897-4287-9-5 · Cited by 46
Predicting survival of men with recurrent prostate cancer after radical prostatectomy
Dell’Oglio, P., Suardi, N. R., Boorjian, S. A., Fossati, N., Gandaglia, G., Tian, Z., Moschini, M., Umberto Capitanio, A., Karakiewicz, P. I., Montorsi, F., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.004 · Cited by 38
Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential
Klein, E. A., Santiago‐Jiménez, M., Yousefi, K., Robbins, B. A., Schaeffer, E. M., Trock, B. J., Tosoian, J. J., Haddad, Z., Ra, S., Karnes, R. J., et al. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.08.091 · Cited by 36
Self-citationAbiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids
Attard, G., Reid, A. H. M., & de Bono, J. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.5170 · Cited by 35
Recent Trends in PSA Testing and Prostate Cancer Incidence
Etzioni, R., & Gulati, R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.6310 · Cited by 34
Diethylstilboestrol for the treatment of prostate cancer: past, present and future
Turo, R., Smolski, M., Esler, R. C., Kujawa, M., Bromage, S. J., Oakley, N. E., Adeyoju, A., Brown, S. C., Brough, R., Sinclair, A. M., et al. (2013) · Scandinavian Journal of Urology · doi:10.3109/21681805.2013.861508 · Cited by 33
Genetic profile of ductal adenocarcinoma of the prostate
Seipel, A. H., Whitington, T., Delahunt, B., Samaratunga, H., Mayrhofer, M., Wiklund, P. N., Grönberg, H., Lindberg, J., & Egevad, L. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.04.015 · Cited by 27
From genome to bedside: Are we lost in translation?
Hayes, D. F. (2013) · The Breast · doi:10.1016/j.breast.2013.07.004 · Cited by 13
Hussaini, A., Olszanski, A. J., Stein, C. A., Bosch, B., & Nemeth, P. R. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3360-3 · Cited by 7
Mikhaylenko, D. S., Tanas, A. S., Zaletaev, D. V., & Nemtsova, M. V. (2020) · Journal of Oncology · doi:10.1155/2020/7363102 · Cited by 3
Cited by
Hofman, M. S., Lawrentschuk, N., Francis, R. J., Tang, C., Vela, I., Thomas, P., Rutherford, N., Martin, J. M., Frydenberg, M., Shakher, R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30314-7 · Cited by 2,040
Genome-wide cell-free DNA fragmentation in patients with cancer
Cristiano, S., Leal, A., Phallen, J., Fiksel, J., Adleff, V., Bruhm, D. C., Jensen, S. Ø., Medina, J. E., Hruban, C., White, J. R., et al. (2019) · Nature · doi:10.1038/s41586-019-1272-6 · Cited by 1,476
Rebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,090
Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B. H., Clarke, N., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.06.002 · Cited by 642
Self-citationArtificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge
Bulten, W., Kartasalo, K., Chen, P.-H. C., Ström, P., Pinckaers, H., Nagpal, K., Cai, Y., Steiner, D. F., van Boven, H., Vink, R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01620-2 · Cited by 543
Metadata
- Authors
- Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., Horwitz, E. M., Hurwitz, M., Ippolito, J. E., Kane, C. J., Kuettel, M. R., Lang, J. M., McKenney, J., Netto, G., Penson, D. F., Plimack, E. R., Pow-Sang, J. M., Pugh, T. J., Richey, S., Roach, M., Rosenfeld, S., Schaeffer, E., Shabsigh, A., Small, E. J., Spratt, D. E., Srinivas, S., Tward, J., Shead, D. A., & Freedman-Cass, D. A.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2019-05
- Volume
- 17
- Issue
- 5
- Pages
- 479-505
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W2945522282
- Cited by
- 1,532
- References
- 198
- FWCI
- 182.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.